{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"246.35","value":"685.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Ixazomib 4 mg, capsules, orally, once on Days 1, 8, and 15; lenalidomide 25 mg, capsules, orally, once on Days 1 through 21; and dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15, and 22 of a 28-day treatment cycle until progressive disease (PD) or unacceptable toxicity (up to 20 cycles)","id":"OG000","title":"Ixazomib+Lenalidomide+Dexamethasone"}],"paramType":"MEAN","populationDescription":"Participants from the PK-evaluable population, all participants who received protocol-specified dosing during Cycle 1, did not receive any excluded concomitant medications and had sufficient concentration-time data to permit reliable estimation of PK parameters, with data available for analysis.","reportingStatus":"POSTED","timeFrame":"Cycle 1, Day 1 pre-dose and multiple time-points (up to 168 hours) post-dose","title":"AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for Ixazomib","type":"PRIMARY","unitOfMeasure":"hr*ng/mL"}